Samsung Ushers in a New Era of Diagnostic Solutions at RSNA 2023

Samsung will feature the latest innovation in cutting-edge mobile computed tomography, including the state-of-the-art OmniTom Elite with Photon Counting Detector (PCD) technology

NeuroLogica Corp., a subsidiary of Samsung Electronics Co. Ltd. and a pioneer in premium diagnostic imaging solutions, will showcase its latest offerings in mobile computed tomography (CT) and feature the OmniTom® Elite Photon Counting mobile CT scanner at the Radiological Society of North America (RSNA) Annual Meeting in Chicago from November 26 to November 30.

The clinical launch of the OmniTom Elite with PCD, the first US FDA 510(k) cleared single-source photon counting computed tomography scanner with a single detector on a mobile system, will be featured at this year’s meeting. Photon counting is a next-generation CT technology that sorts the different energies of X-rays after they have passed through the scan field, capturing the X-ray photons directly at the detector and converting the energy to electrical signals.

The OmniTom Elite’s ability to provide versatile, real-time mobile imaging enables healthcare providers to administer point-of-care CT to critical patients without the need to transport them to a separate department, expanding the diagnostic possibilities of CT at the patient’s bedside.

Upgrading capabilities were top of mind when designing OmniTom Elite mobile CT scanners. In the near term, all current OmniTom users will have the opportunity to upgrade their scanners with the PCD technology. Meanwhile, a limited number of premier research partners will aid in developing the full potential of OmniTom Elite with PCD.

The University of Dundee has partnered with NeuroLogica to collaborate on research aimed at pushing the boundaries of medical imaging in healthcare.

“With NeuroLogica’s new, emerging technologies, we are currently witnessing the biggest innovation in imaging in the last decade,” said Professor Iris Grunwald, Chair of Neuroradiology at The University of Dundee.

This has allowed NeuroLogica to build on design features from the first US FDA US 510(k) clearance in 2022 to the second one in June 2023, to include high resolution mode scanning and multi-energy CT functionality with spectral capability for material decomposition and virtual monoenergetic images (VMI).*

“The OmniTom Elite is an advanced imaging solution that is extremely mobile, giving healthcare providers more flexibility in when and where they run diagnostic tests for their patients,” said Renaud Maloberti, Head of Business, MCT. “We look forward to featuring this innovative technology at this year’s Radiological Society of North America Annual Meeting.”

Massachusetts General Hospital is also collaborating with NeuroLogica and testing the OmniTom Elite with PCD to monitor post-trauma and post-surgical patients.

“Availability of photon-counting detector technology on a mobile head CT platform is a significant advance in the development of CT,” said Rajiv Gupta, PhD, MD, Neuroradiology Division Chief of Massachusetts General Hospital and Associate Professor at Harvard Medical School. “This advance heralds a new era of CT applications in stroke, trauma, ICU and intra-op settings.”

NeuroLogica will showcase its innovation at Booth #6113, McCormick Place, and unveil the OmniTom Elite with PCD on Sunday, November 26 at 10:30 am CST, with a live demonstration of this state-of-the-art technology.

Also on Sunday, November 26 from 11:45 am to 12:45 pm CST in the South Building, Level 4, Room S403B, McCormick Place, Dr. Rajiv Gupta of Massachusetts General Hospital and Professor Iris Grunwald of the University of Dundee will host the Samsung NeuroLogica Lunch & Learn Event “Photon Counting: The Next Generation of Neuro CT.” They will discuss how leveraging the latest innovation in CT applications may increase productivity and enhance the patient and physician experience.

For more information or to register, visit www.eventcreate.com/e/samsungrsna2023.

*OmniTom Elite with PCD may not be commercially available in some countries. OmniTom Elite with PCD is only supported for adult axial imaging for head and neck.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy